Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.

Naruhiko IshiwadaRina AkaishiYasuhiro Kobayashi Kanae Togo Naohiro Yonemoto Moe Matsuo Shinnosuke KanekoAmy W LawKazumasa Kamei

Published in: Infectious diseases and therapy (2024)

A combined prophylaxis of year-round RSVpreF vaccine and palivizumab could be a cost-effective strategy to protect neonates throughout the infant stage (< 1 years old) in Japan.

Keyphrases

respiratory syncytial virus
low birth weight
pregnancy outcomes
preterm infants
preterm birth